PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

Sponsor
Massachusetts General Hospital
Study ID
NCT07739537
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Diabete Type 2
  • Pharmacogenomic Drug Interaction

Eligibility Criteria

Sex
ALL
Age
18 Years - 79 Years
Healthy Volunteers
Not accepted

Interventions

  • Orforglipron — DRUG
    Orforglipron challenge after baseline MMTT

Study Details

We are conducting a research study to learn how the body responds to food through different genetic pathways and how these responses may change during a short course of orforglipron. Orforglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist that was approved by the U.S. Food and Drug Administration (FDA) on April 1, 2026, for long-term weight management. In longer studies, it has helped people lose weight and improve blood sugar, blood pressure, and cholesterol. By taking part, you will receive detailed metabolic testing and may receive study results that provide additional information about your blood sugar and metabolic health.

Key Dates

First listed
Jul 31, 2026
Start date
Oct 1, 2026
Status verified
Jul 2026
Primary completion
Sep 30, 2029
Completion
Sep 30, 2030

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Drug challenge
    MMTT after 12 doses of orforglipron 2.5 mg
  • No Intervention: Baseline
    MMTT pre-drug challenge

Primary Outcome Measure

Physiologic characterization by MMTT [ Time Frame: 1 day ]

Central Contacts

Related Studies